A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) (NCT06655246)
A Phase 1a/1b Study of the Safety, Pharmacokinetics, and Antitumor Activity of the Oral Menin Inhibitor Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) After Imatinib Failure
🩺 Plain-English Summary (8th-Grade Level)
In this clinical trial, the safety, tolerability, and preliminary antitumor activity of ziftomenib in combination with imatinib will be evaluated in adults with gastrointestinal stromal tumors (GIST) who have been treated previously with imatinib.
Who can join: Review the eligibility criteria below.
Location: University of Alabama at Birmingham — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (32 Sites)
Showing the first 25 of 32 sites.
- University of Alabama at Birmingham — Birmingham, Alabama
- Mayo Clinic Cancer Center — Phoenix, Arizona
- University of California, San Diego — La Jolla, California
- University of Southern California — Los Angeles, California
- University Of California, Irvine — Orange, California
- Stanford Cancer Institute — Palo Alto, California
- UCLA Santa Monica Medical Center — Santa Monica, California
- University of Colorado Cancer Center — Aurora, Colorado
- Sarah Cannon Research Institute — Denver, Colorado
- Yale University School of Medicine — New Haven, Connecticut
- Mayo Clinic Cancer Center — Jacksonville, Florida
- University of Miami — Miami, Florida
- Northwestern University — Chicago, Illinois
- University of Iowa — Iowa City, Iowa
- Johns Hopkins University — Baltimore, Maryland
- Massachusetts General Hospital — Boston, Massachusetts
- Harvard University — Boston, Massachusetts
- University of Michigan — Ann Arbor, Michigan
- Mayo Clinic Cancer Center — Rochester, Minnesota
- Memorial Sloan-Kettering Cancer Center — New York, New York
- Duke University Medical Center — Durham, North Carolina
- Ohio State University — Columbus, Ohio
- Oregon Health & Science University — Portland, Oregon
- Thomas Jefferson University — Philadelphia, Pennsylvania
- Temple University Health System — Philadelphia, Pennsylvania
📞 Contact the Study Coordinator
Phone: (844) 587-2662
Email: medinfo@kuraoncology.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Gastrointestinal Stromal Tumor (GIST)
Explore by condition: All Gastrointestinal Stromal Tumor (GIST) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.